Atum, Phylex accelerate universal SARS coronavirus vaccine

By The Science Advisory Board staff writers

June 15, 2020 -- Atum and Phylex BioSciences will collaborate to advance research toward creating a universal vaccine effective against pathogenic coronaviruses, including the novel coronavirus SARS-CoV-2.

Through the partnership, Atum will utilize its Leap-in-Transposase platform to develop the cell line required for Phylex's universal severe acute respiratory syndrome (SARS) coronavirus vaccine candidate.

The Phylex antigen candidate contains epitopes similar to the receptor-binding domain of the SARS coronavirus spike protein. Copies of the antigen are displayed on a virus-like particle that self-assembles after being secreted by the cell line in development by Atum.

The collaboration will enable Phylex to develop the vaccine candidate while simultaneously conducting immunogenicity studies, noted co-founder and Chief Executive Officer Pascal Brandys in a press release. Brandys added that the company's objective is to develop a universal vaccine candidate with an associated manufacturing and clinical development plan by fall 2020.

Moderna moves COVID-19 vaccine to late-stage clinical trial
Moderna has finalized phase III clinical study protocols for its mRNA-1273 COVID-19 vaccine candidate in coordination with the U.S. Food and Drug Administration...
J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...
Panacea, Refana collaborate on COVID-19 vaccine
Panacea Biotec and Refana are partnering on an inactivated virus-based vaccine for COVID-19 through a joint venture company that will be based in Ireland.
FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...
Atum gives labs free access to protein production platform
Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter